ICANS and mortality after CAR-T therapy for NHL patients can be predicted using physical function measures of falls, balance and strength deficits, and use of an assistive device. - Suppr | 超能文献

相似文献

1

ICANS and mortality after CAR-T therapy for NHL patients can be predicted using physical function measures of falls, balance and strength deficits, and use of an assistive device.

Bone Marrow Transplant. 2025 Sep 18. doi: 10.1038/s41409-025-02714-y.

2

Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy.

Transplant Cell Ther. 2025 Sep 13. doi: 10.1016/j.jtct.2025.09.017.

3

Prescription of Controlled Substances: Benefits and Risks管制药品的处方：益处与风险

4

Patient Restraint and Seclusion患者约束与隔离

5

Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis.嵌合抗原受体 T 细胞疗法治疗实体器官移植受者淋巴瘤的疗效和毒性：系统评价和荟萃分析。

Transplant Cell Ther. 2024 Jan;30(1):73.e1-73.e12. doi: 10.1016/j.jtct.2023.05.018. Epub 2023 Jun 4.

6

The importance of trunk muscle strength for balance, functional performance, and fall prevention in seniors: a systematic review.躯干肌肉力量对老年人平衡、功能表现和预防跌倒的重要性：系统评价。

Sports Med. 2013 Jul;43(7):627-41. doi: 10.1007/s40279-013-0041-1.

7

Neuroimaging Findings in Children and Young Adults With Neurotoxicity After CAR T-Cell Therapy for B-Cell Malignancies.接受CAR T细胞疗法治疗B细胞恶性肿瘤后出现神经毒性的儿童和青年的神经影像学表现

Neurology. 2025 Oct 7;105(7):e214086. doi: 10.1212/WNL.0000000000214086. Epub 2025 Sep 8.

8

Baseline Cognitive and Neurological Status Does Not Modify the Occurrence of ICANS in CAR T-Cell Therapy for Aggressive B-Cell Lymphoma.基线认知和神经学状态不会改变侵袭性B细胞淋巴瘤CAR-T细胞治疗中免疫效应细胞相关神经毒性综合征（ICANS）的发生情况。

Eur J Neurol. 2025 Jun;32(6):e70236. doi: 10.1111/ene.70236.

9

Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.嵌合抗原受体 T 细胞治疗后免疫效应细胞相关神经毒性综合征的临床表现、危险因素和结局：系统评价。

Transplant Cell Ther. 2022 Jun;28(6):294-302. doi: 10.1016/j.jtct.2022.03.006. Epub 2022 Mar 11.

10

CLOX and neurotox: Utility of the clock drawing task in monitoring for immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T-cell therapy.CLOX与神经毒素：在嵌合抗原受体T细胞治疗后监测免疫效应细胞相关神经毒性综合征中画钟试验的效用

Br J Haematol. 2025 Oct;207(4):1495-1503. doi: 10.1111/bjh.70044. Epub 2025 Jul 28.

本文引用的文献

1

Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma.基线血清炎症蛋白预测弥漫性大 B 细胞淋巴瘤中嵌合抗原受体 T 细胞治疗结局不良。

Blood Cancer Discov. 2024 Mar 1;5(2):106-113. doi: 10.1158/2643-3230.BCD-23-0056.

2

Physical function, nutritional status, and quality of life before and after chemotherapy in patients with malignant lymphoma.恶性淋巴瘤患者化疗前后的身体功能、营养状况和生活质量。

Medicine (Baltimore). 2023 Feb 10;102(6):e32901. doi: 10.1097/MD.0000000000032901.

3

CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.